Suntec Medical, Inc.
- Biotech or pharma, therapeutic R&D
Suntec Medical’s MINC technology is an advanced platform of ADC technology.
MINC is superior to ADC by:
o Delivers 100-1000x more drug to the brain
o Repair damaged neuron to regain normal brain functions.
o Remove drug toxicity to a safe level.
Three leading products from MINC technology are STM-001, STM-002 and STM-003:
STM-001
o Expected to treat >90% brain cancers.
o Phase I trials in M.D. Anderson and John Hopkins.
STM-002
o An immunotherapy able to treat 40+ types of cancers.
o Expect phase 1 trials in Q4 2027.
STM-003
o The only drug for early- and late-stage Alzheimer's (AD)
o Recover normal cognition.
o Expect phase I trials in Q2, 2026
Suntec is seeking:
1. Funding to support the clinical trials
2. Out-license these 3 drug candidates and others in preclinical/discovery
3. Customer MINC formulation to enhance brain delivery for clients
*Please No CRO/CMO meeting requests.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}